General Clinical Chemistry Analyzers and Accessories
Abcam V-9302, 5MG
MW 538.7 Da, Purity >=98%. A competitive antagonist of transmembrane glutamine flux, that selectively targets the amino acid transporter ASCT2 (SLC1A5). V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀ = 9.6 μM) in HEK-293 cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 50MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 50MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Prostaglandin A1, 5MG
MW 336.5 Da. Endogenous prostaglandin with diverse biological actions including anti-hypertensive, anti-inflammatory, anti-viral and anti-cancer properties.
The product is subject to the following: Abcam Restricted Use Statement
Abcam D-Gluconic acid, methyl ester, 50MG
MW 210.18 g/mol. Membrane permeant analog of D-gluconic acid. Useful as a component of cell culture media; enzymatic degradation of xylan and glucomannan; various pharmaceutical preparations; as well as an intermediate in carbohydrate based synthetic preparations of sugar derivatives.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 100MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Qstatin, 5MG
MW 293.2 Da, Purity >=98%. A potent, and selective Vibrio QS inhibitor which affects Vibrio harveyi LuxR homologues, the well-conserved master transcriptional regulators for QS in Vibrio species. QStatin binds tightly to a putative ligand-binding pocket in SmcR, the LuxR homologue in V. vulnificus, and changes the flexibility of the protein, thereby altering its transcription regulatory activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT-3025 hydrochloride, 5MG
MW 606.2 Da, Purity >=98%. SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating RelA/p65 lysine 310, critical for activation of the NF-κB signaling pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GLPG-1690, 5MG
MW 588.7 Da, Purity >=98%. Selective autotaxin inhibitor with potential application in idiopathic pulmonary disease (IPF).
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 100MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 10MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Binimetinib, MEK1/2 inhibitor, 25MG
MW 441.2 Da, Purity >99%. Potent and selective allosteric inhibitor of MEK1/2. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam WAY-316606, 5MG
MW 448.5 Da, Purity >=98%. A secreted Frizzled-Related Protein-1 (sFRP-1) inhibitor (IC₅₀ = 0.65 μM). It blocks sFRP-1 from interacting with Wnt and thus increases Wnt signaling.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Apatinib, 25MG
MW 441.9 Da. Potent and selective inhibitor of VEGFR2, IC₅₀ = 1 nm. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement